Article Text

Download PDFPDF
Rapid clinical mutational testing of KRAS, BRAF and EGFR: a prospective comparative analysis of the Idylla technique with high-throughput next-generation sequencing
  1. Matthias Van Haele1,2,
  2. Sara Vander Borght2,
  3. An Ceulemans1,
  4. Michiel Wieërs1,
  5. Sofie Metsu3,
  6. Xavier Sagaert1,2,
  7. Birgit Weynand1,2
  1. 1 Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
  2. 2 Pathology, University Hospitals Leuven, Leuven, Belgium
  3. 3 HistoGeneX NV, Edegem, Belgium
  1. Correspondence to Dr Matthias Van Haele, KU Leuven, Leuven 3000, Belgium; matthias.vanhaele{at}


Aims Precision medicine therapy is remodelling the diagnostic landscape of cancer. The success of these new therapies is often based on the presence or absence of a specific mutation in a tumour. The Idylla platform is designed to determine the mutational status of a tumour as quickly and accurately as possible, as a rapid, accurate diagnosis is of the utmost importance for the treatment of patients. This is the first complete prospective study to investigate the robustness of the Idylla platform for EGFR, KRAS and BRAF mutations in non-small cell lung cancer, metastatic colorectal cancer and metastatic melanoma, respectively.

Methods We compared prospectively the Idylla platform with the results we obtained from parallel high-throughput next-generation sequencing, which is the current gold standard for mutational testing. Furthermore, we evaluated the benefits and disadvantages of the Idylla platform in clinical practice. Additionally, we reviewed all the published Idylla performance articles.

Results There was an overall agreement of 100%, 94% and 94% between the next-generation panel and the Idylla BRAF, KRAS and EGFR mutation test. Two interesting discordant findings among 48 cases were observed and will be discussed together with the advantages and shortcoming of both techniques.

Conclusion Our observations demonstrate that the Idylla cartridge for the EGFR, KRAS and BRAF mutations is highly accurate, rapid and has a limited hands-on time compared with next-generation sequencing.

  • precision medicine therapy
  • next-generation sequencing
  • idyllatm
  • EGFR
  • KRAS
  • BRAF

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Runjan Chetty.

  • Contributors MVH and SVB conceived and designed the study; SVB, MVH, AC and SM performed the experiments; MVH and MW analysed the literature; MVH and SVB wrote the manuscript; Biocartis provided the cartridges; BW and XS supervised the study.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval Ethical Committee of the University Hospitals of Leuven.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as online supplementary information.